In renal cell carcinoma, a second-generation MTOR inhibitor, MLN0128, was used to treat realistic patient-derived tissue slice grafts and showed decreased levels of 4EBP1, c-Myc, and p-S6K1 [73]. Here, MTOR is linked to hereditary clear cell renal cell carcinoma.